Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Facial Palsy Induced by Covaxin in Adolescent Female - A Rare Case Report

Author(s): Priyanka Jivrambhai Chaudhari*, Uditkumar Bhupeshkumar Chawda, Bhagirath Jayantilal Bhad, Ashvin Vasantlal Mevada* and Sushilkuamar Gopikant Jha

Volume 18, Issue 4, 2023

Published on: 17 January, 2023

Page: [603 - 605] Pages: 3

DOI: 10.2174/1574886318666221228120829

Price: $65

Abstract

Background: The world has seen nearly 2 years of a pandemic caused by the SARS-CoV-2 virus, notoriously known as COVID-19. Several vaccines have been approved under Emergency Use Authorization (EUA) to combat the disease, one of which is Covaxin, an inactivated adjuvant SARSCoV- 2 vaccine that is generally well tolerated and has fewer side effects. However, we recently have seen a rare case of facial palsy (paralysis) following Covaxin vaccination in an adolescent girl.

Case Presentation: A 16 years old adolescent girl presented with chief complaints of left side deviation of mouth with difficulty in closing right eye after 29 days of receiving the first dose of Covaxin, which was finally diagnosed as a "Covaxin induced facial palsy". Her symptoms were alleviated with some supportive measures, steroid and antiviral treatment, with full recovery.

Conclusion: The case depicts facial nerve paralysis following Covaxin use, possibly the first of its kind. This case illustrates plausible explanation to Covaxin use and occurrence of facial palsy, however, further studies required to establish causal relationship.

Keywords: Facial paralysis, COVID-19, SARS-CoV-2, vaccines, adverse event/reaction, adjuvant, immunization.

« Previous Next »
[1]
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[2]
World Health Organization. Background document on the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: Background document to the WHO Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19, 3 November 2021. InBackground document on the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: Background document to the WHO Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19. 2021. Availlable from: https://apps.who.int/iris/handle/10665/347044
[3]
Adjuvant developed with NIH funding enhances efficacy of India’s COVID-19 vaccine. National Institutes of Health (NIH). 2021. https://www.nih.gov/news-events/news-releases/adjuvant-developed-nih-funding-enhances-efficacy-indias-Covid-19-vaccine
[4]
Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis 2021; 21(7): 950-61.
[http://dx.doi.org/10.1016/S1473-3099(21)00070-0] [PMID: 33705727]
[5]
World Health Organization. Causality assessment of an adverse event following immunization (AEFI): User manual for the revised WHO classification. Geneva: World Health Organization. 2013. Availlable from: https://apps.who.int/iris/handle/10665/80670
[6]
Rath B, Gidudu JF, Anyoti H, et al. Facial nerve palsy including Bell’s palsy: Case definitions and guidelines for collection, analysis, and presentation of immunisation safety data. Vaccine 2017; 35(15): 1972-83.
[http://dx.doi.org/10.1016/j.vaccine.2016.05.023] [PMID: 27235092]
[7]
Rowhani-Rahbar A, Klein NP, Lewis N, et al. Immunization and Bell’s palsy in children: A case-centered analysis. Am J Epidemiol 2012; 175(9): 878-85.
[http://dx.doi.org/10.1093/aje/kws011] [PMID: 22411861]
[8]
Zhang W, Xu L, Luo T, Wu F, Zhao B, Li X. The etiology of Bell’s palsy: A review. J Neurol 2020; 267(7): 1896-905.
[http://dx.doi.org/10.1007/s00415-019-09282-4] [PMID: 30923934]
[9]
House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg 1985; 93(2): 146-7.
[http://dx.doi.org/10.1177/019459988509300202] [PMID: 3921901]
[10]
Shemer A, Pras E, Einan-Lifshitz A, Dubinsky-Pertzov B, Hecht I. Association of COVID-19 vaccination and facial nerve palsy: A case-control study. JAMA Otolaryngol Head Neck Surg 2021; 147(8): 739-43.
[http://dx.doi.org/10.1001/jamaoto.2021.1259] [PMID: 34165512]
[11]
Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med 2004; 350(9): 896-903.
[http://dx.doi.org/10.1056/NEJMoa030595] [PMID: 14985487]
[12]
Principi N, Esposito S. Do vaccines have a role as a cause of autoimmune neurological syndromes? Front Public Health 2020; 8: 361.
[http://dx.doi.org/10.3389/fpubh.2020.00361] [PMID: 32850592]
[13]
Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell’s palsy. N Engl J Med 2004; 350(9): 860-1.
[http://dx.doi.org/10.1056/NEJMp048006] [PMID: 14985482]
[14]
Ozonoff A, Nanishi E, Levy O. Bell’s palsy and SARS-CoV-2 vaccines. Lancet Infect Dis 2021; 21(4): 450-2.
[http://dx.doi.org/10.1016/S1473-3099(21)00076-1] [PMID: 33639103]

Rights & Permissions Print Cite
Article Metrics
31
1
© 2024 Bentham Science Publishers | Privacy Policy